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Summary
The mechanisms by which Mdm2 and Mdm4 (MdmX) regulate p53 remain controversial. We generated a mouse encoding
p53 lacking the proline-rich domain (p53DP). p53DP exhibited increased sensitivity to Mdm2-dependent degradation and
decreased transactivation capacity, correlating with deficient cell cycle arrest and reduced apoptotic responses. p53DP
induced lethality inMdm22/2 embryos, but not inMdm42/2 embryos.Mdm4 loss did not alter Mdm2 stability but significantly
increased p53DP transactivation to partially restore cycle control. In contrast, decreasing Mdm2 levels increased p53DP
levels without altering p53DP transactivation. Thus, Mdm4 regulates p53 activity, while Mdm2 mainly controls p53 stability.
Furthermore, Mdm4 loss dramatically improved p53DP-mediated suppression of oncogene-induced tumors, emphasizing
the importance of targeting Mdm4 in chemotherapies designed to activate p53.Introduction
Stringent regulation of p53 in response to stress is essential to
suppress tumor formation. p53 is a transcription factor main-
tained at low levels under normal conditions. Upon stress, it is
stabilized and activated to induce the transcription of genes in-
volved in cell cycle arrest, apoptosis, and DNA repair (Wahl
et al., 2005, for review). Nontranscriptional mechanisms for ap-
optosis induction have also been proposed (Chipuk et al., 2004).
A complex interplay of numerous proteins regulates p53. For ex-
ample, the interaction of the histone acetyl transferase p300
with the p53 N-terminal transactivation domain (TAD) is impor-
tant for efficient transactivation, but the same TAD is inhibited
by interaction with Mdm2 and its related family member
Mdm4 (also called MdmX) (Marine and Jochemsen, 2005). The
stability of p53 is regulated primarily by the E3 ubiquitin-ligase
activity of Mdm2, with possible additional contributions from
other ubiquitin ligases (Pirh2, COP1, Birc6), the ubiquitin-
specific protease HAUSP, and other modulators such as ARF,
Pin1, or YY1 (Brooks and Gu, 2004; Mantovani et al., 2004;
Ren et al., 2005; Sui et al., 2004). The importance of this pathway
in tumor suppression is indicated by p53 mutations in >50% of
human cancers, andMdm2 or Mdm4 overexpression in many ofCANCER CELL 9, 273–285, APRIL 2006 ª2006 ELSEVIER INC. DOI 10.10the remainder (Danovi et al., 2004; Vassilev et al., 2004; Vousden
and Lu, 2002).
The contribution of p53 structure to target gene regulation re-
mains to be resolved. For example, the proline-rich domain
(PRD), defined by residues 58–98 of human p53, contains 15
prolines and five repeats of the amino acid motif PXXP (where
P designates proline and X any amino acid; Figure 1A). PXXP
motifs can create binding sites for SH3 (Src homology 3) do-
mains, and the p53 PXXPs appear to affect interaction with
the histone acetyl transferase p300 (Dornan et al., 2003). The
PRD also may modulate Mdm2-mediated degradation, since
the conformation of prolines in the PRD can be changed upon
binding of the prolyl isomerase Pin1 after stress to reduce
Mdm2 binding (Mantovani et al., 2004). These and other data
implicate the PRD in p53 stability control, p53-mediated trans-
activation, and transcription-independent apoptosis (Berger
et al., 2001; Chipuk et al., 2004; Dumaz et al., 2001; Edwards
et al., 2003). However, transfection studies have produced con-
flicting data concerning the contribution of the PRD to p53 func-
tional output. Walker and Levine (1996) showed that a human
p53 lacking residues 62–91 (p53DP) was stabilized after stress
but compromised for growth suppression (Figure 1A). Later
studies reported that p53DP is able to induce cell cycle arrestS I G N I F I C A N C E
This work presents a p53mutant protein able to rescue lethality causedbyMdm4deficiency. This unique property allowed us to test the
effects ofMdm4 loss onMdm2andp53 stability, andp53 transactivation and function in vivo.Our results are not consistentwith previous
models of p53 regulation by Mdm2 and Mdm4, but rather suggest an alternative regulation model. Furthermore, chemotherapeutic
strategies designed to activate p53 in tumors have so far focusedon interferingwithMdm2.Our finding thatMdm4deficiency improves
the capacity of a mutant p53 to suppress oncogene-induced tumors offers genetic evidence that additional strategies should be de-
signed to abrogate p53-Mdm4 interactions. Our results suggest that Mdm2 and Mdm4 antagonists could cooperate to activate p53.16/j.ccr.2006.03.014 273
A R T I C L EFigure 1. Targeting the p53DP mutation at the mouse p53 locus
A: Human p53 is a protein of 393 amino acids with five proposed domains:
the transactivation (TAD), proline-rich (PRD), specific DNA binding (DBD),
tetramerization (4D), and C-terminal regulatory (CT) domains. The human
PRD is detailed below, with prolines (P) in bold and PXXP motifs underlined.
Empty boxes: residues deleted in p53DP mutants from (a) Walker and Levine
(1996); (b) Hengstermann et al. (1998).
B: Residues 55–95 of murine p53 are shown, with prolines and PXXPs as in A.
Empty boxes: residues deleted in p53DP mutants from (a) Sakamuro et al.
(1997) (with an additional insertion of two residues); (b) Edwards et al.
(2003). Gray box (g): residues deleted here.274but not apoptosis (Baptiste et al., 2002; Chipuk et al., 2004; Roth
et al., 2000; Sakamuro et al., 1997; Venot et al., 1998; Zhu et al.,
1999) and proposed that p53DP transactivates p21 but not cru-
cial proapoptotic genes (Roth et al., 2000; Venot et al., 1998). An
alternative would be that p53DP cannot induce transcription-
independent apoptosis because it does not bind Bcl-xL (Chipuk
et al., 2004). Taken together, the data suggest that the PRDmay
be a molecular switch that enables p53 to induce either apopto-
sis or cell cycle arrest.
Further analysis of p53DP could give insight into the regulation
of p53 by its negative regulators, Mdm2 and Mdm4, as the pre-
cise mechanisms remain controversial. Deficiency of either
Mdm2 orMdm4 results in early embryonic lethality, which is res-
cued by loss of p53. Mdm2 deficiency leads to deathw3.5 days
post coitum (dpc), due to elevated apoptosis (Jones et al., 1995;
Montes de Oca Luna et al., 1995) that is partially rescued by Bax
deficiency (Chavez-Reyes et al., 2003). Mdm4 deficiency
causes lethality later, apparently by cell proliferation arrest
(Finch et al., 2002; Migliorini et al., 2002; Parant et al., 2001)
that is partially rescued by p21 loss (Steinman et al., 2004).
The differences in timing and cause of embryonic lethality led
to the proposal that Mdm2 and Mdm4 regulate nonoverlapping
p53 functions, with Mdm2 regulating apoptosis and Mdm4 reg-
ulating cycle arrest (Parant et al., 2001). However, Mdm4 was
soon after shown to regulate apoptosis in some tissues in vivo
(Finch et al., 2002; Migliorini et al., 2002). Another model to ex-
plain the inability of either regulator to compensate for the loss
of the other postulates an interdependent relationship in which
Mdm4 stabilizes Mdm2, while Mdm2 enables nuclear import
of Mdm4 (Gu et al., 2002). While the results of one study were
consistent with this model (Gu et al., 2002), later studies dis-
agreed (Danovi et al., 2004; Linares et al., 2003). Thus, the
important questions of whether Mdm4 and Mdm2 are interde-
pendent, and how they control p53, remain unanswered.
We generated mice in which the p53 PRD was deleted to gain
insight into its functional contributions under conditions that
maintain physiologically relevant levels of p53 pathway compo-
nents. This is critical, as altering the level of Mdm2 relative to
p53DP profoundly affects the stability and transactivation ability
of this mutant (Berger et al., 2001; Dumaz et al., 2001). Most
p53DP studies have been performed on human p53. Since the
PRD is loosely conserved, the deletion we introduced was
based on a study showing that a deletion of six prolines and
C: Targeting strategy. The 11 exons of wild-typep53are contained in a 17 kb
EcoRI fragment. The targeting construct (below) contains: a 50 homology re-
gion (with exons 1–6; 4* designates the mutated exon), a floxed Neo gene
(LNeoL), a 30 homology region (exons 7–9), and a Thymidine Kinase gene
(TK). Targeted recombinants are G418 and gancyclovir resistant, result
from the described crossing-overs, and are detected by Southern blot
with the indicated probe as containing a 9 kb band. Cre expression in the
male germline subsequently allows excision of Neo.
D: ES clones analyzed as described in C. Clone 3 contains a wild-type 17 kb
fragment and a recombinant 9 kb fragment.
E: Mouse genotyping by PCR. The mutant product (DP) is shorter by 51 bp.
F: p53 mRNAs were quantified in wild-type and p53DP/DP cells using real-time
PCR, normalized to control mRNA levels, and the ratio of p53DP/p53WT mRNA
was determined. Results are from three independent experiments. Error bar
represents SD.
G: Distribution of the offspring from intercrosses of p53+/DP mice. Obs: ob-
served; exp: expected numbers assuming a Mendelian distribution without
sex distortion. The distribution conforms to expected values (y = 5; c2 = 2.19 <
15.09).CANCER CELL APRIL 2006
A R T I C L Eboth PXXPs of murine p53 induced cell cycle arrest but not ap-
optosis, as observed for human p53DP (Sakamuro et al., 1997;
Figure 1B). The analysis of the p53DP mutant mouse we gener-
ated challenges the p53DP phenotype identified from many
transfection studies, provides insight into Mdm2 and Mdm4
functions, and demonstrates in vivo that eliminating Mdm4 is
required for optimal p53 activation and p53-mediated tumor
suppression. Consequently, inhibiting both Mdm2 and Mdm4
should be considered a prime objective for anticancer strate-
gies.
Results
Targeting of a p53DP mutation in the mouse
We used homologous recombination in ES cells to delete six
prolines and both PXXP motifs (Figures 1B and 1C; Figure S1
in the Supplemental Data available with this article online). The
ES cells contain PrmCre, a Cre-recombinase transgene ex-
pressed specifically in spermatocytes (O’Gorman et al., 1997).
Targeted recombinants were identified by Southern blot with
a probe from intron 9 (Figure 1D), and single integration events
were verified with a Neo probe (data not shown). Candidate
clones were confirmed by PCR and injected into blastocysts
to generate chimeric mice. PCR verified germline transmission
of the mutation and was used to genotype the mouse colony
(Figure 1E). We isolated RNA from p53DP/2 MEFs and se-
quenced the entire coding region: the p53DP sequence was
identical to the wild-type p53 (p53WT) sequence except for the
deletion of nucleotides encoding the PRD. The quantification
of p53 mRNAs from wild-type and p53DP/DP MEFs demon-
strated identical p53 transcription from both alleles (Figure 1F).
We intercrossed p53+/DPmice to assess the role of p53DP dur-
ing development. Intercrosses of p53+/2mice lead to a reduced
yield of p532/2 animals resulting from a defect in neural tube
closure, most likely caused by defective apoptosis, leading to
exencephaly and death in 25% of female p532/2 embryos
(reviewed in Miller et al., 2000). By contrast, intercrossing
p53+/DPmice yielded no underrepresentation of female mutants
(Figure 1G), suggesting that p53DP retains enough proapoptotic
activity to ensure normal neural tube formation.
p53DP is a weak transactivator with increased sensitivity
to Mdm2
p53WT and p53DP were present at very low levels in unstressed
cells, in which no or very faint nuclear signals were observed.
Upon adriamycin (ADR) treatment, both accumulated in nuclei,
but p53DP appeared to accumulate less than p53WT (Figure 2A).
p53DP is a less efficient transactivator than p53WT and exhibits
target gene-specific differences in efficiency: Mdm2 and PUMA
mRNA were w1.5 times lower in p53DP/DP than in wild-type
ADR-treated MEFs, while p21 and Noxa mRNA levels were
w3-fold lower (Figure 2B). The reduced efficiency on the p21
promoter was so severe that p21 mRNA levels were similar in
ADR-treated p53DP/DP MEFs and unstressed wild-type cells.
Western blots confirmed that p53DP accumulated 2-3 times
less than p53WT after ADR, and that p53DP is a less effective in-
ducer of p21 than Mdm2 (Figure 2C). The reduced transcription
response was not due to a difference in damage kinase-medi-
ated phosphorylation of p53DP (see Figure S2).
Since p53DP was proposed to be more sensitive to Mdm2-
mediated degradation than p53WT (Berger et al., 2001; DumazCANCER CELL APRIL 2006et al., 2001), we determined if the lower p53DP protein levels after
ADR treatment correlated with reduced protein stability. Be-
cause Mdm2 targets p53 for degradation by the proteasome,
we first used MG132 to verify that inhibition of the proteasome
increased p53DP levels, and then Nutlin 3a, which prevents
Mdm2-p53 interaction (Vassilev et al., 2004), to demonstrate
that p53DP degradation is Mdm2 dependent (Figure 2D). Direct
evidence that p53DP is more sensitive to Mdm2-mediated deg-
radation than p53WT came from analysis of heterozygous MEFs
in which the p53WT and p53DP proteins are exposed to the same
intracellular Mdm2 concentration. In these cells, p53DP levels
were four to five times less than p53WT (Figure 2E), and the
half-life of p53DP was significantly reduced (Figure 2F). Finally,
we analyzed the effects of varying Mdm2 gene copy number
in p53+/+, p53+/DP, and p53DP/DP cells: decreased Mdm2 in-
creased p53WT accumulation only marginally but markedly
increased p53DP levels (Figure S3). Thus, p53DP is stabilized af-
ter ADR treatment but is far more sensitive to Mdm2-mediated
degradation than p53WT.
Basal p53 levels were low in unstressed wild-type and
p53DP/DP cells, but p53DP abundance was similar to or higher
than that of p53WT (see Figure 2C and below). This probably de-
rives from the lower Mdm2 levels in unstressed p53DP/DP MEFs
(Figures 2B and 2C). Following g-irradiation, p53DP was more
abundant that p53WT at most time points, but p53DP induced
less Mdm2 and p21 (Figure 2G). Thus damage-specific effects
were observed, as p53DP accumulated less than p53WT after
ADR (Figure 2C), but more than p53WT after irradiation (Fig-
ure 2G). Q-PCR clarified these data by revealing that p53DP
more robustly activates Mdm2 after ADR compared to irradia-
tion (see Figures 2H and 2B). Thus, p53DP is exquisitely sensitive
to Mdm2, and its accumulation relies on the level of Mdm2 gen-
erated by the activating stress.
We used chromatin immune precipitation (ChIP) to determine
whether the stress- and gene-specific differential transactiva-
tion of p21 and Mdm2 resulted from promoter-specific binding
differences. Although p53DP transactivates p21 less well than
Mdm2 after ADR (Figure 2B), it binds both target promoters sim-
ilarly, and about two to three times less efficiently than p53WT
(Figure 2I). Furthermore, the relative binding of p53DP to the
Mdm2 promoter did not differ significantly after ADR or irradia-
tion (Figure 2I), even though stress-specific differences inMdm2
transactivation were observed (Figures 2B and 2H). Thus, the
differences in transactivation cannot be explained by differ-
ences in DNA binding. Rather, they may result from differential
capacities in recruiting transcription factors and/or coactivators
at promoters, as recently proposed for another p53 mutant ex-
hibiting stress- and gene-specific differences (Johnson and At-
tardi, 2005).
p53DP/DP cells exhibit a deficient arrest response
but retain a proapoptotic response
We next analyzed p53DP function in cell cycle and apoptosis
control. Consistent with the low p21 expression in stressed
p53DP/DP cells (Figure 2), irradiation and ADR doses that induce
cell cycle arrest in wild-type MEFs failed to arrest p53DP/DP
MEFs (Figures 3A and 3B). Low p21 levels may also account
for the inability of p53DP/DP cells to undergo replicative senes-
cence (data not shown). The lack of developmental defects in
p53DP/DPmice, however, suggested that p53DP may be compe-
tent to induce apoptosis (Figure 1G). We tested this by analyzing275
A R T I C L EFigure 2. Accumulation and transactivation ability of p53DP in response to DNA damage
A: p532/2, wild-type, and p53DP/DP MEFs were left untreated (Unt) or treated with adriamycin (ADR) at 0.5 mg/ml for 24 hr, then stained with antibodies against
p53 (green) and phalloidin (red), and their DNA was counterstained with DAPI (blue).
B: RNAs from wild-type and p53DP/DP (DP) MEFs treated as in A were quantified using real-time PCR. Results are from three independent experiments. For each
of the tested genes, the results were first normalized to control mRNA levels, then the mean amount of mRNAs in unstressed wild-type cells was assigned a value
of 1. Gray bars: unstressed cells, Black bars: stressed cells. Error bars represent SD.
C: Wild-type and p53DP/DP MEFs were treated as in A, then protein extracts were immunoblotted with antibodies to Mdm2, p53, p21, and actin. Low/high ex-
posures are designated lo x/hi x.
D: Extracts were prepared from p53DP/DP MEFs left untreated, or treated with 10 mM MG132 (left), or 10 mM Nutlin (right) for 4 hr.
E: p53+/DP MEFs were treated and analyzed as in C.
F: p53DP has a shorter half-life than p53WT in p53+/DP stressed MEFs. Cells were treated as in A, then incubated with cycloheximide (CHX) for the indicated times
(in minutes). Graph shows half-life determinations. p53 bands were normalized to actin, then to the first time points. A decrease of one unit of log2 (band in-
tensity) equals one half-life.
G: Wild-type and p53DP/DP MEFs were left untreated (2), or submitted to 12 Gy irradiation, and protein extracts were prepared 1, 2, 4, or 8 hr after irradiation.
H: RNAs from wild-type and p53DP/DP (DP) MEFs treated as in G were quantified and plotted as in B. Results are from three independent experiments. Error bars
represent SD.
I: ChIP assay of p21 and Mdm2 promoters was performed in p532/2 (KO), wild-type, and p53DP/DP (DP) MEFs after ADR or 12 Gy g-irradiation. For each stress
condition, p53 bound response elements were purified with polyclonal antibody CM-5, quantified using real-time PCR, normalized to input DNA, then ex-
pressed as a fraction of bound response elements in wild-type cells (wild-type = 1). Results are from three (ADR) or two (g-irradiation) independent experi-
ments. Error bars represent SD.276 CANCER CELL APRIL 2006
A R T I C L EMEFs sensitized to apoptosis by E1A overexpression (Lowe
et al., 1993). An ADR dose that induced apoptosis inw50% of
wild-type MEFs (0.25 mg/ml) elicited little response in p53DP/DP
cells, while higher ADR doses produced similar responses in
wild-type and p53DP/DP cells (Figure 3C). Similarly, 2.5 mM eto-
poside induced apoptosis in w50% of wild-type cells and few
if any p53DP/DP cells, while 10 mM etoposide induced significant
apoptosis in both genotypes. The low level of apoptosis in
p532/2 cells under both conditions indicated that apoptosis
was largely p53 dependent (Figure 3D). We next tested the ap-
optotic response of E1AMEFs after 6 or 12 Gy irradiation. About
25% of irradiated wild-type cells underwent apoptosis, while
a significant, but reduced apoptotic response was observed in
p53DP/DP cells (Figure 3E, left). However, we observed variations
in the irradiation-induced apoptotic responses of p53DP/DP cells:
few p53DP/DP cells were apoptotic in an experiment with 20%
apoptotic wild-type cells (Figure 3E, right, black bars), while sig-
nificant p53DP/DP apoptosis was observed in two experiments
with 30% apoptotic wild-type cells (Figure 3E, right, gray
bars). By contrast, significant apoptosis was never observed
in irradiated p532/2 cells (Figure 3E). Apoptosis in irradiated
p53DP/DP thymocytes in vivo was also variable: apoptotic
p53DP/DP thymocytes were detected in an experiment with
50% apoptotic wild-type cells, but not in two experiments with
30% apoptotic wild-type cells, and apoptotic p532/2 cells
were never detected (data not shown). In sum, p53DP exhib-
its a measurable, but significantly compromised apoptotic
response.
p53DP rescues Mdm4 null but not Mdm2 null embryos
The embryonic lethalities resulting from Mdm2 or Mdm4 loss
provide a powerful assay for analyzing the functionality of hypo-
morphic p53 alleles. As p53DP exhibited different capacities for
apoptosis and cell cycle control, we determined if it exhibited
a differential capacity to rescue lethality due to Mdm2 or Mdm4
deficiency. No p53DP/DP Mdm22/2 mice were observed from
intercrosses of p53DP/DP Mdm2+/2mice (Table 1, upper), or from
p53+/DP Mdm2+/2 intercrosses (data not shown). In striking con-
trast, viable p53DP/DP Mdm42/2 mice were obtained in Mende-
lian proportions from intercrosses of p53DP/DP Mdm4+/2 (Table
1, lower) or p53+/DP Mdm4+/2 mice (data not shown). p53DP/DP
Mdm42/2mice did not exhibit overt phenotypic abnormalities.
Mdm4 deficiency augments p53DP functions
without affecting Mdm2 stability
The rescue of Mdm42/2 mice by p53DP enabled analysis of the
consequences of Mdm4 loss on p53 regulation in vivo. Mdm4
loss significantly decreased the proliferation rate of p53DP/DP
cells (Figure 4A). Importantly, unlike p53DP/DP MEFs, irradiated
p53DP/DP Mdm42/2 MEFs did arrest. However, the arrest re-
sponse was still not as efficient as that observed in wild-type
cells (Figures 4B and 3A). Consistent with a decreased prolifer-
ation rate and partially restored arrest response, p21 protein
levels were elevated in both unstressed and ADR-treated
p53DP/DP Mdm42/2 cells (Figure 4C). Mdm4 loss also resulted
in higher Mdm2 levels and lower p53DP levels after ADR (Fig-
ure 4C). Similarly, g-irradiated p53DP/DP Mdm42/2 cells ex-
hibited higher p21 and Mdm2 levels than p53DP/DP cells, and
lower p53DP levels at later time points (Figure 4D).
We tested whether the increased p21 and Mdm2 protein
levels inMdm42/2 cells resulted from increased transactivationCANCER CELL APRIL 2006by p53DP, since both are p53 target genes and Mdm4 has no
p53-independent effects on cell proliferation or cycle control
(Migliorini et al., 2002). Q-PCR analyses are consistent with
this idea (Figure 4E). However, Mdm4 loss did not significantly
increase the binding of p53DP to the corresponding promoters
(data not shown).
One model based on transfection studies is that Mdm4 stabi-
lizes Mdm2 (Gu et al., 2002). According to this model, Mdm4
loss should destabilize Mdm2, leading to elevated p53 levels.
As we did not observe this, we tested themodel directly by com-
paring Mdm2 stability in the presence and absence of Mdm4.
Strikingly, Mdm4 deficiency did not alter Mdm2 stability in un-
stressed or DNA damaged cells (Figure 4F).
Mdm2 and Mdm4 affect p53DP function
by different mechanisms
We varied Mdm2 andMdm4 gene dosage in p53DP/DP MEFs to
determine their relative contributions to p53 regulation. As
p53DP/DP Mdm22/2 MEFs could not be isolated, we compared
p53DP/DP Mdm2+/2, p53DP/DP Mdm4+/2, p53DP/DP Mdm2+/2
Mdm4+/2, and p53DP/DP Mdm42/2 MEFs. Each genotype par-
tially restored the arrest response of p53DP (Figures 5A and
4B). Western blots revealed that the loss of one Mdm2 or
Mdm4 gene copymodestly increased p21 levels, cells heterozy-
gous for both Mdm2 and Mdm4 expressed slightly more p21,
andMdm42/2 cells expressed the highest p21 levels (Figure 5B).
Consistent with our previous observations (Figure 4), the p53DP
levels were decreased in stressed cells with only one or no
Mdm4 alleles, presumably because of their elevated Mdm2
levels. In contrast, Mdm2+/2 cells exhibited lower Mdm2 levels
correlating with a significant increase in p53DP abundance
(Figure 5B).
We gained insight into the mechanisms by which each nega-
tive regulator may function by analyzing how the induction of
p21 varied with the amount of p53DP present in cells of each ge-
notype (Figure 5B). Reducing Mdm2 gene dosage significantly
increased p53DP levels, compensating for the poor transactiva-
tion activity of p53DP to generate higher p21 levels. By contrast,
reducedMdm4 gene dosage resulted in significantly decreased
p53DP levels, yet p53DP was able to induce p21 even more effi-
ciently. Thus, in Mdm42/2 cells the elevated Mdm2 levels en-
gendered more efficient p53DP degradation, but the remaining
p53DP was a more efficient transcriptional activator.
p53DP suppression of tumor growth is enhanced
by reducing Mdm2 and Mdm4 expression,
or by eliminating Mdm4
We compared spontaneous tumor onset in wild-type, p532/2,
and p53DP/DP mice. While all p532/2 mice developed fatal tu-
mors within 10 months, very few tumors were found after 12
months in p53DP/DP mice (Figure 6A). We detected thymic lym-
phomas and sarcomas in p53DP/DP mice, tumor types associ-
ated with p53 deficiency in mice (Donehower et al., 1992), but
too few mice have been analyzed thus far to define a tumor
spectrum. The delayed onset of spontaneous tumors in p53DP
mice is reminiscent of that of mice expressing p53R172P (also
called p53515C; Liu et al., 2004). The p53R172P mutant also re-
tains only part of its tumor suppressor functions. However, the
tumors that form later in these animals are very aggressive
and grow rapidly. One hypothesis is that the enfeebled277
A R T I C L EFigure 3. p53DP does not induce cell cycle arrest but can induce apoptosis
A:Cell cycle control was analyzed inp532/2 (KO), wild-type, andp53DP/DP (DP) MEFs, in asynchronous cell populations left untreated, or 24 hr after 6 or 12 Gy g-
irradiation. On top, a typical experiment for cells of each genotype is shown. Results are fromR8 independent experiments andR2 independent MEFs. As-
terisks indicate significant differences after irradiation.
B: Cell cycle control was analyzed as in A, in asynchronous cell populations left untreated, or treated for 24 hr with 0.5 mg/ml ADR. Results are from four inde-
pendent experiments.278 CANCER CELL APRIL 2006
A R T I C L Ep53R172P protein does not efficiently suppress tumor growth in
clones where oncogenic events have occurred (Liu et al., 2004).
We tested if a similar situation applied to p53DP, by analyzing
the ability of p53DP to suppress oncogene-induced tumors. A
constant number of E1A- and Ras-expressing (E1A + Ras)
p53+/+, p532/2, and p53DP/DP MEFs was injected into the flanks
of nude mice, and the weights of age-matched tumors were
compared after 10–15 days. E1A + Ras p532/2 cells generated
large tumors in all mice, while E1A + Ras p53+/+ did not. Impor-
tantly, E1A + Ras p53DP/DP cells showed very little, if any sup-
pression of oncogene-induced tumor growth (Figure 6B). We
also determined the ability of p53DP to suppress oncogene-
induced tumors in cells with reduced levels of Mdm2 and/or
Mdm4.Half the genedosage for eitherMdm2orMdm4 improved
tumor suppression marginally, if at all. However, decreasing the
gene dosage for both Mdm2 and Mdm4 showed a 4-fold de-
crease in tumor size. Strikingly, the number and size of tumors
generated from E1A + Ras p53DP/DP Mdm42/2MEFs were sim-
ilar to those fromE1A +Ras p53+/+MEFs (Figure 6B). These data
provide in vivo evidence that the specific inhibition of Mdm4 can
dramatically improve tumor suppression.
Discussion
p53 is a transcription factor capable of inducing death, senes-
cence, cell cycle arrest, or DNA repair. Complex regulatory
mechanisms determine the appropriate response. The p53 N
terminus plays an essential role in this regulation, with multiple
N-terminal serines and threonines phosphorylated after dam-
age, and at least two domains, the TAD and PRD, that contribute
to Mdm2 and Mdm4 binding. Phosphorylation of the N-terminal
serines was proposed to diminish Mdm2 binding while enhanc-
ing coactivator association. However, analyses of p53 serine-al-
anine mutants indicate that these residues are modulators of,
rather than essential for, p53 activation (e.g., Chao et al.,
2003). In sharp contrast, subtle changes in the levels of Mdm2
and Mdm4 can profoundly affect p53 activation and tumor sup-
pression (Bond et al., 2004; this report). Recent studies also
show that DNA damage induces phosphorylation of Mdm2
and Mdm4 to alter their stability and access to p53 (see below).
In sum, factors that regulate the abundance, stability, and asso-
ciation of Mdm2 and Mdm4 with p53 combine to trigger a p53
response. This study employed genetic strategies in the mouse
to show that the p53 PRD significantly contributes to Mdm2-
mediated control of p53 stability, that Mdm2 and Mdm4 differ-
entially regulate p53, and that Mdm4 inhibition can augment
tumor suppression by p53.
p53DP, a hypomorphic protein exquisitely sensitive
to Mdm2 control
Our study shows that a targeted PRD deletion made p53 more
sensitive to Mdm2 (Figures 2E and 2F and Figure S3) andCANCER CELL APRIL 2006affected its ability to induce target genes (Figures 2B and 2C).
Moreover, p53DP/DP cells were unable to induce cell cycle arrest
but could induce apoptosis (Figure 3). This phenotype is surpris-
ing compared to that observed inmany transfection studies (see
Introduction). An inability to induce cell cycle arrest is readily ex-
plained by weak transactivation of p21 by p53DP. Reducing
Mdm2 or Mdm4 levels partially restored p21 induction and cell
cycle arrest in p53DP/DP cells (Figures 4 and 5). This result em-
phasizes that, as for p53WT, the balance between p53DP and
these two inhibitors is critical for proper p53 regulation. Accu-
rate reproduction of the physiologic balance between p53,
Mdm2, and Mdm4 is difficult to achieve by transfection, which
could explain why the in vivo and transfection analyses gener-
ated different phenotypes. An additional important factor is
that the endpoints of the PRD deletion can affect the ability of
the mutant to induce an apoptotic response (Edwards et al.,
2003). Taken together, we suggest that the PRD may have
evolved to fine-tune Mdm2 (and possibly Mdm4) binding, which
in turn impacts on stability control and transcriptional output.
Analyses in progress will determine whether the PRD functions
as a structural regulator dependent on proline isomerization
(Mantovani et al., 2004), as a protein interaction domain such
as PXXP (Dornan et al., 2003), or merely as a spacer between
the TAD and the DNA binding domain.
Analysis of p53DP regulation by Mdm2 and Mdm4
suggests an alternative model for p53 control
In a wild-type context, Mdm2 loss leads to embryonic death due
to elevated apoptosis, while Mdm4-deficient embryos die
mainly from cell proliferation arrest (see Introduction). It is strik-
ing that the compromised function of p53DP fails to rescue
Mdm2 loss but fully rescues Mdm4 deficiency (Table 1). The
sensitivity of the hypomorphic p53DP mutant to Mdm2 and
Mdm4 also affords a larger dynamic range within which to eval-
uate their contributions to p53 stability and functional output.
Table 1. p53DP rescues Mdm4 deficiency, but not Mdm2 deficiency
ap53DP/DP Mdm2+/2 3
p53DP/DP Mdm2+/2
No. of mice:
obs (exp) Total
p53DP/DP Mdm2+/+ 23 (23) 93
p53DP/DP Mdm2+/2 70 (47)
p53DP/DP Mdm22/2 0 (23)
bp53DP/DP Mdm4+/2 3
p53DP/DP Mdm4+/2
No. of mice:
obs (exp) Total
p53DP/DP Mdm4+/+ 16 (23) 91
p53DP/DP Mdm4+/2 53 (45)
p53DP/DP Mdm42/2 22 (23)
aOffspring from p53DP/DP Mdm2+/2 intercrosses. Observed (obs) values differ
from expected (exp) Mendelian ratios (y = 2; c2 = 35.13 > 9.21).
bOffspring from p53DP/DP Mdm4+/2 intercrosses. The distribution conforms to
Mendelian expected values (y = 2; c2 = 3.46 < 9.21).C: E1A expressing p532/2, p53+/+, and p53DP/DP MEFs were left untreated or treated with indicated doses of ADR for 24 hr. On top, a typical experiment for cells
of each genotype is shown. Results are fromR6 independent experiments and R2 independent MEFs. Asterisks indicate significant increases in apoptotic
cells (apoptosis in a fraction of untreated cells (particularly in wild-type MEFs) most likely reflects mild stresses generated by E1A expression and cell culture).
D: Apoptosis was analyzed as in C, in E1A-expressing MEFs, untreated or treated with 2.5 or 10 mM etoposide for 24 hr. Results are from three independent
experiments.
E:Apoptosis in untreated E1A-expressing MEFs or 24 hr after 6 or 12 Gy irradiation. Left shows results averaged from three independent experiments; right shows
the individual experiments, respectively, in black bars, dark gray bars, and light gray bars.
Error bars indicate SD.279
A R T I C L EFigure 4. Consequences of the loss of Mdm4
A: The proliferation of p532/2 (KO), p53DP/DP (DP), p53DP/DP Mdm42/2 (DP M42/2), and wild-type MEFs was compared using a 3T3 protocol. Each point is
a mean value from two independent MEFs, the value for each MEF resulting from duplicate plates. Starting from 33 105 cells, 1012p53DP/DP cells were obtained
after eight passages, corresponding tow22 cell doublings (cd; 3 3 105 3 222 = 1.2 3 1012). Only 1010 p53DP/DP Mdm42/2 MEFs were counted (w15 cd). Thus,
Mdm4 loss slows down p53DP/DP cell doubling byw30% (1 – 15/22 = 0.3).
B: Cell cycle arrest in p53DP/DP Mdm42/2 (DP M42/2) MEFs was analyzed and plotted as in Figure 3A. Results are from two independent MEFs inR7 indepen-
dent experiments. Error bars represent SD.
C: p53DP/DP and p53DP/DP Mdm42/2 MEFs were left untreated or treated with ADR as before.
D:Wild-type,p53DP/DP, andp53DP/DPMdm42/2MEFs were left untreated (2), or submitted to 12 Gy irradiation, and protein extracts were prepared 2–24 hr after
irradiation.
E: RNAs from p53DP/DP (DP) and p53DP/DP Mdm42/2 (DP M42/2) MEFs treated as in D were quantified using real-time PCR and plotted as in Figure 3. Results are
from three independent experiments.
F: Mdm2 half-life in p53DP/DP and p53DP/DP Mdm42/2 MEFs. Cells, unstressed or 2 hr after 12 Gy irradiation, were incubated with CHX for the indicated times
(in minutes). For half-life determination, Mdm2 bands were normalized to actin, then to the first time point.280 CANCER CELL APRIL 2006
A R T I C L EWestern analyses showed that deleting even a single copy of
Mdm2 significantly increased p53DP levels, leading to increased
transactivation of p53 target genes (Figure 5B). We infer that to-
tal absence of Mdm2 allows p53DP to accumulate sufficiently to
exceed Mdm4, resulting in continuous activation of cell cycle
arrest and apoptotic genes to induce lethality. In addition,
Figure 5. Effects on p53DP of a reduction in Mdm4 and/or Mdm2 gene
dosage
A: Cell cycle arrest in p53DP/DP Mdm2+/2 (DP M2+/2), p53DP/DP Mdm4+/2 (DP
M4+/2), and p53DP/DP Mdm2+/2Mdm4+/2 (DP M2+/2M4+/2) MEFs was an-
alyzed and plotted as in Figure 3A. Results are, for each genotype, from two
independent MEFs inR7 independent experiments. Error bars represent SD.
B: p53DP/DP, p53DP/DP Mdm2+/2, p53DP/DP Mdm4+/2, p53DP/DP Mdm2+/2
Mdm4+/2, and p53DP/DP Mdm42/2 MEFs were left untreated or treated
with ADR as before. The graph below indicates the ratio between band in-
tensities for p21 and p53DP in stressed cells of each genotype, with a value of
1 assigned to the ratio in p53DP/DP cells.CANCER CELL APRIL 2006extremely high p53DP levels could participate in a transcription-
independent apoptosis response. By contrast, total loss of
Mdm4 resulted in less abundant, but more active p53DP (Figures
4 and 5B). Lower p53DP levels would be unlikely to induce tran-
scription-independent apoptosis. More importantly, in the ab-
sence of Mdm4, p53DP activated more Mdm2 (Figures 4 and
5B). This Mdm2 had unfettered access to p53DP, creating the
classic Mdm2-p53 negative feedback loop. In MEFs, Mdm4 de-
ficiency in a p53DP/DP background increased p21 levels, but the
levels were clearly inadequate to arrest embryonic develop-
ment. It is possible that reducing p21 to an acceptable level ex-
plains how p53DP fully rescues Mdm4 loss, since total absence
of p21 merely delays death and shifts the cause of lethality from
proliferation arrest to apoptosis (Chavez-Reyes et al., 2003;
Steinman et al., 2004). Another explanation is that p53DP, due
to its higher sensitivity to Mdm2, may fail to activate additional
target genes that contribute to lethality in p53WT animals lacking
Mdm4.
In a p53WT context, the death of both Mdm2- and Mdm4-
deficient mice indicated that each inhibitor is normally unable
to compensate for the loss of the other. Two models were pro-
posed to explain this observation. One postulates that Mdm2
and Mdm4 regulate nonoverlapping functions of p53, with
Figure 6. p53DP delays the onset of spontaneous tumors but is a poor sup-
pressor of oncogene-induced tumor xenografts
A: The cumulative survival of wild-type, p53DP/DP, and p532/2 mice after 1
year was compared. Data are from R40 animals for each genotype.
Cause-specific survival was used; mice affected by causes other than tu-
mors were censored.
B: E1A + Ras xenograft assay. Results are expressed as the relative weight of
age-matched tumors, with a value of 1 given to the average weight from
p532/2 cells. Results are from R7 tumors for each genotype. Asterisks note
tumor sizes significantly lower than that from p53DP/DP cells. Error bars repre-
sent SD.281
A R T I C L EFigure 7. The p53DP mutant suggests two different roles for Mdm2 and Mdm4 in controlling p53 function
A: Information gained by analyzing p53DP in different Mdm2 and Mdm4 genetic contexts. p53DP and p21 levels after ADR (Figures 2, 4, and 5) were used to
estimate p53 stability and activity. A1: The transcriptional response (blue/green striped square) is the product of p53 accumulation (blue circle) by p53 ac-
tivation (green star). Relative values for these parameters in wild-type cells are diagrammed for reference. A2: p53DP accumulation and activation in
p53DP/DP cells. The accumulation of p53DP is 1/3, and the transcriptional response 1/4 of that observed in wild-type cells (Figure 2). The sizes of the circle,
star, and square vary accordingly. Mdm2-Mdm4-p53 interactions are represented to enable comparisons below. This is a simplified view, in that only the over-
all interactions of the three proteins are drawn, rather than the dynamics of their interactions with each other or other proteins. The data suggest that Mdm4 is
an important inhibitor of p53DP activity (by TAD occlusion; orange), while Mdm2 mainly regulates p53DP accumulation (through ubiquitination; red). Mdm2 also
targets itself and Mdm4 for degradation, which we suggest is important to initiate/strengthen the p53 response (see B). Activated p53DP transactivates Mdm2
(green) to establish a negative feedback loop. A3: Effects of Mdm4 deficiency on p53DP. The p53DP response is increased, through a combined decreased
p53DP accumulation and increased p53DP activation (Figures 4 and 5). As Mdm2 stability is independent of Mdm4 (Figure 4), the increased Mdm2 levels limit
p53DP accumulation. Mdm4 would play a predominant role in TAD occlusion, since p53DP activity is higher in Mdm42/2 cells despite increased Mdm2 levels.
The increased p53DP transcriptional response remains lower than that observed in wild-type cells (striped squares, Figure 4), accounting for p53DP/DP Mdm42/2
mice viability. A4: Effects of reduced Mdm2 on p53DP. The p53DP response is increased through an increase in p53DP accumulation and a modest decrease in
p53DP activation (Figure 5). Reduced Mdm2 reduce p53DP degradation, leading to increased p53DP accumulation, but the reduced Mdm2 also compromises
Mdm4 degradation, mitigating p53DP activation.
B:A dynamic model of the p53 response that takes into account the relative contributions of Mdm2 and Mdm4 to p53 regulation. B1: In unstressed cells, p53 is
kept at low levels (due to Mdm2-mediated ubiquitination) and inactive (due primarily to Mdm4-mediated TAD occlusion). (For simplicity, we have not in-
cluded the effects of ATM, Chk2, or HAUSP, discussed in Marine and Jochemsen [2005].) B2: Upon stress, Mdm2 degrades itself and Mdm4, leading to the
accumulation and activation of p53. B3:As activated p53 transactivates Mdm2, the increasingly abundant Mdm2 degrades Mdm4 more efficiently, allowing
full p53 activation. B4: Upon stress relief, the accumulated Mdm2 now preferentially targets p53, which decreases p53 levels to potentially enable cell cycle
reentry.Mdm2 regulating apoptosis and Mdm4 regulating cell cycle ar-
rest (Parant et al., 2001). The other proposes a mutual depen-
dence of the regulators, in which Mdm4 stabilizes Mdm2 and
Mdm2 enables nuclear import of Mdm4 (Gu et al., 2002). We
showed that loss of one copy of Mdm2, or of one or both
Mdm4 alleles, increased p21 levels and partially restored cycle
control. This observation, together with data indicating that
Mdm4 can regulate apoptosis (Finch et al., 2002; Migliorini
et al., 2002; Xiong et al., 2006; Francoz et al., 2006) or that282Mdm2 overexpression can rescue Mdm4 loss (Steinman et al.,
2005), is difficult to reconcile with the model of nonoverlapping
p53 functions. Our data also clearly show that loss of Mdm4
does not alter Mdm2 stability (Figure 4F), in clear contrast to
the predictions of the mutual dependency model. In fact, be-
cause Mdm4 loss translates into a relative decrease in p53DP
levels after damage, our results further suggest that Mdm2
does not require Mdm4 to regulate its own stability, or the stabil-
ity of p53DP.CANCER CELL APRIL 2006
A R T I C L EOur results suggest a third model in which Mdm2 and Mdm4
contribute in distinctly different ways to p53 control. We found
that Mdm4 loss significantly activates p53DP (Figure 5B). The
observation thatMdm4 is produced at constant levels and binds
the p53 TAD in the same region as Mdm2 suggests that Mdm4
functions to antagonize p53 activity under nonstressing condi-
tions when Mdm2 levels are low (Marine and Jochemsen,
2005). Here, we observed higher p53DP activity in stressed
Mdm42/2 cells, indicating that p53DP inhibition by Mdm4 is
not restricted to unstressed conditions. As Mdm2 levels oscil-
late during the DNA damage response (Lev Bar-Or et al.,
2000), the ratio betweenMdm4 andMdm2 should also vary dur-
ing a stress response, which may account for our observation.
Importantly, our data also show that the elevated p53DP present
in cells with reduced Mdm2 expression is markedly less active
on a per molecule basis than p53DP in cells lacking Mdm4.
Even more surprising was our finding that p53DP does not ap-
pear more active, on a per molecule basis, in p53DP/DP
Mdm2+/2 cells than in p53DP/DP cells (Figure 5B). Our data thus
suggest a functional complementarity of Mdm2 and Mdm4, in
which Mdm4 acts as a major inhibitor of p53 transcriptional ac-
tivity, while Mdm2 mainly regulates p53 stability. Importantly,
while this manuscript was under revision a similar conclusion
was derived from studies using conditional activation of a
LoxStopLoxp53 allele (Francoz et al., 2006). This indicates the rel-
evance of the p53DP mutant for understanding regulation of
wild-type p53.
The observation that decreased Mdm2 levels stabilize but do
not activate p53DP seems paradoxical, because the classic neg-
ative feedback loop postulates that Mdm2 regulates p53 stabil-
ity through ubiquitination, and activity by binding the p53 TAD.
However, several recent reports reveal another role for Mdm2
in p53 control: Mdm2 auto-degradation and Mdm2-dependent
degradation of Mdm4 after DNA damage (Chen et al., 2005; Ka-
wai et al., 2003; Meulmeester et al., 2005; Okamoto et al., 2005;
Pereg et al., 2005; Stommel andWahl, 2004). The degradation of
both negative regulators is critical for p53 activation, as protea-
some inhibition prevents DNA damage from activating p53
(Stommel and Wahl, 2004). Thus, Mdm2 is required to both
inhibit p53 in the classic negative feedback loop, and to also
activate p53 through a positive process involving accelerated
degradation of itself andMdm4 after stress.We suggest that en-
gagement by the proteasome makes both inhibitors less avail-
able for p53 binding, which facilitates p53 activation and accu-
mulation. Thismodel could explain why decreasingMdm2 levels
appears to have little effect on p53DP activity: inMdm2+/2 cells,
less Mdm2 would bind the p53 TAD, but Mdm4 would be de-
graded less efficiently. According to this, only when sufficient
Mdm4 is degraded by Mdm2 does p53 become fully activated.
Our findings and the p53 regulation model they suggest are
summarized in Figure 7.
Augmenting p53DP tumor suppression by Mdm4
deficiency: Implications for anticancer strategies
Given that p53DP is a modest transactivator, we were surprised
to find that it suppresses spontaneous tumor formation rather
effectively (Figure 6A). On the other hand, it is a poor suppressor
of oncogene-induced tumorigenicity in a xenograft model (Fig-
ure 6B). These observations may be explained in two ways.
First, p53DP resembles the p53R172P DNA binding domain mu-
tant in that both induce a subset of p53 functions related toCANCER CELL APRIL 2006tumor suppression, but the latter exhibited a functional output
opposite of p53DP in that it induced cell cycle arrest and not ap-
optosis (Liu et al., 2004). Yet, like p53DP, p53R172P delayed tumor
onset. It is possible that a subset of p53 output is required to
suppress spontaneous tumor formation, but a more complete
response is required inmore advanced stages,whena collection
of potent oncogenic mutations have occurred. A second possi-
bility is that classic p53 target genes that regulate apoptosis and
cell cycle control are not those that contribute most to prevent-
ing initiation of spontaneous tumors. We also observed that
reducing the gene dosage of either Mdm2 or Mdm4 marginally
affected the growth of oncogene-induced tumors. However,
far more significant effects were observed by decreasing the ex-
pression of both regulators, or by the absence of Mdm4 activity
(Figure 6B).
Inhibiting the interaction between p53 and Mdm2 has been
recognized as an attractive anticancer strategy for many years.
Several approaches revealed that antibodies and small mole-
cules that bind Mdm2 in its p53 binding pocket may stabilize
p53 and activate the p53 pathway (Vassilev et al., 2004 and ref-
erences therein). Because the p53 binding domains of Mdm2
and Mdm4 are similar, these reagents might also antagonize
Mdm4 binding, though it is unclear to what extent. We note
that Mdm2 binding to p53 is stabilized by a ‘‘lid’’ that differs sig-
nificantly in Mdm4 (McCoy et al., 2003). Consequently, optimal
Mdm2 antagonists may not be optimal Mdm4 antagonists, as
exemplified by SuperTip 12/1, which antagonizes Mdm2 11
times more efficiently than Mdm4 (Bottger et al., 1999). The
search for optimal Mdm4 antagonists is clinically important,
since Mdm4 amplification and overexpression occur in 20% of
lung, breast, and colon tumors, the three most common human
cancers (Danovi et al., 2004). In addition, our results provide
both the rationale and experimental evidence that optimal an-
tagonists to Mdm2 and Mdm4 could synergize to ensure strong
p53 activation in tumors.
Experimental procedures
Targeting construct
Mouse genomic wild-type p53 DNA was obtained from combining a 17 kb
EcoRI fragment (from L. Donehower) and a 6 kb BamHI fragment (from T.
Jacks). A 0.7 kb XhoI-XbaI fragment containing exon 4 was subcloned and
mutated as described in Figure S1.
Targeting/genotyping
PrmCre 129/SvJae embryonic stem (ES) cells were electroporated with the
targeting construct linearized with NotI. Of 197 G-418 and ganciclovir-resis-
tant ES clones, two candidates were identified by Southern blot, confirmed
by PCR (primer sequences available upon request), and injected into blasto-
cysts. Germline transmission was verified by genotyping MEFs from breed-
ings of chimeras with p53+/2 mice. RT-PCR of RNAs from p53DP/2 MEFs
showed that the mutant cDNA differed from the p53WT sequence only by
the deletion of nucleotides encoding aa 75–91 (sequence available upon re-
quest). Mouse mutants KO for p53 (Taconic),Mdm2 (kind gift of G. Lozano),
and Mdm4 (kind gift of S.N. Jones) were genotyped according to published
protocols. All experiments were performed according to IACUC regulations.
Cells and reagents
Primary MEFs were isolated from 13.5 day embryos, genotyped, and cul-
tured, unless noted otherwise, for a maximum of four passages in DMEM
with 15% FBS, 2-mercaptoethanol (100 mM), L-glutamine (2 mM), and anti-
biotics. Cells were g-irradiated at RT with a 60 Co g-irradiator, or treated with
ADR, etoposide, MG132, or Nutlin 3a (kind gift of L. Vassilev). For half-life de-
terminations, cells were treated with 100 mg/ml cycloheximide.283
A R T I C L EImmunofluorescence
MEFs were cultured on collagen-coated coverslips, exposed to ADR, and
analyzed 24 hr later. Coverslips were stained with the p53 antibody CM-5
(Novacastra) and secondary antibodies Alexa Fluor 488 goat-a-mouse
IgG2A and Alexa Fluor 568 goat-a-rabbit (Molecular Probes). Images were
captured on an epifluorescence microscope using equal exposure times
for all images for each fluor.
Western blots
Protein lysates were prepared and analyzed on SDS-PAGE gels as described
(Stommel and Wahl, 2004). Blots were probed with primary antibodies
against p53 (CM-5), p53 phospho-serine 18 (Cell Signaling Technologies),
Mdm2 (2A10), p21 (C-19, Santa Cruz), and a-actin (Sigma). Peroxidase-
conjugated secondary antibodies were detected using Pierce Supersignal
West Pico chemiluminescent substrate. NIH Image 1.63 was used for band
density quantification.
Q-PCR
Total RNA was extracted using RNeasy mini kit (Qiagen) and reverse tran-
scribed using Superscript III RT (Invitrogen). Real-time quantitative PCR
was performed on an ABI PRISM 7700 system using Platinum SYBR Green
mastermix. Primer sequences for detecting cDNA sequence of p53, p21,
Mdm2, Noxa, PUMA, and ARP and PPIA are available upon request.
ChIP assay
The procedure for ChIP assay was detailed recently (Nister et al., 2005).
Retrovirus preparation and infection of MEFs
Cells were infected with the pWZL-E1A12S virus, or were sequentially
infected with pWZL-E1A12S and pBABE-HrasV12 viruses as previously
described (Krummel et al., 2005). Importantly, populations of E1A- or
E1A + Ras-expressing cells were used in all analyses, not individual clones,
to minimize potential differences in expression levels that could result from
independent viral insertion sites.
Flow cytometry
For cell cycle analysis, log phase cells were irradiated with 6 or 12 Gy g-irra-
diation and incubated for 24 hr, or treated for 24 hr with ADR. Cells were then
pulse labeled for 1 hr with BrdU (10 mM), fixed in 70% ethanol, and double
stained with FITC anti-BrdU and propidium iodide, then analyzed as de-
scribed (Krummel et al., 2005). Apoptosis assays were performed on E1A-
expressing MEFs irradiated with 6 or 12 Gy g-irradiation and incubated for
24 hr, or treated for 24 hr with ADR or etoposide, then harvested, stained
with annexin V-FITC and analyzed using Facscan.
Tumorigenicity
Spontaneous tumor onset was determined in mice ofR75% C57Bl/6 back-
ground. All mice in the cohort were >1 year old when survival curves were
plotted. For oncogene-induced tumor assays, we injected 5 3 106 E1A +
Ras-expressing MEFs of the different genotypes subcutaneously into the
rear flank of 6-week-old female athymic nude mice. After 10–15 days, mice
were sacrificed and tumors were isolated and weighed. All experiments
were performed according to IACUC regulations.
Statistical analyses
Offspring were compared to Pearson c2 distribution tables with appropriate
degrees of freedom (y) and 99% confidence (details upon request). For
QPCR, ChIP, cell cycle, apoptosis, and xenograft tumor assays, means 6
SD are shown.
Supplemental data
The Supplemental Data include three supplemental figures and can be found
with this article online at http://www.cancercell.org/cgi/content/full/9/4/273/
DC1/.
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